Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial - 08/09/11
Abstract |
OBJECTIVE: To evaluate the efficacy of intravenous cyclophosphamide pulse therapy in patients with optic neuritis associated with systemic lupus erythematosus (SLE).
PATIENTS AND METHODS: Ten consecutive patients with optic neuritis due to SLE whose condition was refractory to corticosteroids and oral immunosuppressants were treated with intravenous cyclophosphamide (0.5 to 1.0 g/m2) monthly for 6 months.
RESULTS: All patients had bilateral eye involvement. One eye was legally blind, and 13 eyes could see only hand movements or count fingers. Six patients had evidence of the secondary antiphospholipid antibody syndrome. Complete recovery in visual acuity occurred in 10 eyes (50%), and a partial response occurred in six eyes (30%); four eyes (20%) had no response. Complete response in the field tests occurred in eight eyes (40%), with a partial response in nine eyes (45%); no improvement occurred in three eyes (15%).
CONCLUSIONS: Intravenous cyclophosphamide pulse therapy seems to be an effective treatment for optic neuritis refractory to corticosteroids, oral immunosuppressants, or both. A randomized controlled trial will be necessary to confirm our results.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 106 - N° 1
P. 65-69 - janvier 1999 Regresar al número
Artículo precedente
- Effects of standing on cerebrovascular resistance in patients with idiopathic orthostatic intolerance
- Giris Jacob, Denis Atkinson, Jens Jordan, John R Shannon, Raffaello Furlan, Bonnie K Black, David Robertson
- Gender differences in medium-chain dicarboxylic aciduria in alcoholic men and women
- Xiaoli Ma, Enrique Baraona, Barry G Goozner, Charles S Lieber
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?